Daejeon, South Korea

Sung-Woo Kim



 

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 30(Granted Patents)


Location History:

  • Seo-gu Daejeon, KR (2014)
  • Daejeon, KR (2009 - 2020)

Company Filing History:


Years Active: 2009-2020

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations of Sung-Woo Kim

Introduction

Sung-Woo Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of nine patents to his name, Kim's work has the potential to impact therapeutic strategies for various cancers.

Latest Patents

Among his latest patents is the "EGFRvIII antibody and composition comprising same." This patent focuses on an antibody that specifically binds to the epidermal growth factor receptor variant III (EGFRvIII). It includes details about the nucleic acid coding the antibody, a vector containing the nucleic acid, and a method for preparing the antibody. This pharmaceutical composition is aimed at treating cancer or tumors. Another notable patent is the "Human antibody specific to c-Met and preparation method thereof." This invention provides a fully human antibody with high affinity and specificity to c-Met, which is crucial for controlling its activity in vivo.

Career Highlights

Sung-Woo Kim has worked with notable companies in the biotechnology sector, including Pharmabcine Inc. and LG Chem, Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in antibody development.

Collaborations

Some of his coworkers include Jin-San Yoo and Weon-Sup Lee. Their collaborative efforts have likely enhanced the research and development processes in which Kim has been involved.

Conclusion

Sung-Woo Kim's innovative work in antibody development showcases his commitment to advancing cancer treatment. His patents reflect a deep understanding of biotechnology and a dedication to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…